I'm sure that you have all noticed that Dr Campbell always seems to include something like this in all his presentations??Gilead Sciences (NASDAQ:GILD) recently agreed to pay $US21 billion for Immunomedics (NASDAQ:IMMU), while Merck & Co (NYSE:MRK) committed $US4.2 billion to Seattle Genetics (NASDAQ:SGEN). Off the back of this news, Dr James Campbell told *: “Where we are compared to a year ago, the number of deals is going through the roof.
Proactive Investors. Patrys also believes that a potential clinic-ready asset complemented by substantial pre-clinical data on platform applications will make a more compelling partnering opportunity.
Ann: Shareholder Newsletter - June 2021, page-10
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.34M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 1853666 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 3325244 | 5 |
View Market Depth
| Last trade - 16.12pm 16/08/2024 (20 minute delay) ? |
| PAB (ASX) Chart |
Day chart unavailable